Alzheimer's disease (AD) is the most common form of dementia. Although the incidence of
AD is high, the rates of diagnosis and treatment are relatively low. Moreover, effective means …

Alzheimer's disease (AD) is the most common age-related form of dementia, associated with
deposition of intracellular neuronal tangles consisting primarily of hyperphosphorylated …

Many conditions can benefit from RNA-based therapies, namely, those targeting internal
ribosome entry sites (IRESs) and their regulatory proteins, the IRES trans-acting factors …

The decades of evidence that showcase the role of amyloid precursor protein (APP), and its
fragment amyloidβ (Aβ), in Alzheimer's disease (AD) pathogenesis are irrefutable. However …

Alzheimer's disease (AD) is a complex multifactorial disorder that poses a substantial
burden on patients, caregivers, and society. Considering the increased aging population …

Rivastigmine (or Exelon) is a cholinesterase inhibitor, currently used as a symptomatic
treatment for mild-to-moderate Alzheimer's disease (AD). Amyloid-β peptide (Aβ) generated …

Alzheimer's disease (AD) is a progressive mental illness characterized by memory loss and
multiple cognitive impairments. In the last several decades, significant progress has been …

Objective: Alzheimer's disease (AD) is a common neurodegenerative disease. This study
was designed to investigate the roles of lncRNA NEAT1/miR-27a-3p axis in AD. Methods …

Structurally and functionally active synapses are essential for neurotransmission and for
maintaining normal synaptic and cognitive functions. Researchers have found that synaptic …

Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder that
heavily burdens healthcare systems worldwide. There is a significant requirement to …